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Summary. Nuclear medicine methods permit the visualisa-
tion of a variety of metabolic and physiological processes all
over the body. Although planar scintigraphy has been found
useful for many questions, detailed spatial information about
the diseased organ can only be obtained with tomographic
methods. Dependent on the radionuclide involved, two dif-
ferent tomographic procedures are available: single photon
emission computed tomography (SPECT) and positron emis-
sion tomography (PET). The first part of this paper describes
shortly the historical development of these methods as well
as their technical and methodological basics. To elucidate
the large variety of possible applications, an overview of
SPECT and PET procedures utilised in research as well as in
clinical practice are presented. Furthermore, both methods are
compared and their individual advantages are pointed out.
Introduction
During the last three decades new powerful imaging pro-
cedures have been developed in medicine to improve the
diagnosis of diseases. The methods differ in their underlying
physical basics, the achievable image and time resolution
and in the kind of information they produce. Whereas the
strengths of computed tomography (CT), magnetic reson-
ance tomography (MRT) and ultrasound (US) lie in the dis-
play of structural information, the attractive characteristics
of nuclear medicine methods are their ability to visualise
a variety of metabolic and physiological processes all over
the body. For this purpose, substrates which take part in
the metabolic and physiological processes are labelled with
radioactive nuclides. The measurement of the radiation emit-
ted by these nuclides produces different kinds of information
needed for the diagnosis. In order to observe the temporal as
well as the spatial dimension of the information tomographic
methods have to be applied. Dependent on the radionuclide
involved, two different tomographic procedures are avail-
able in nuclear medicine: single photon emission computed
tomography (SPECT) and positron emission tomography
(PET). The purpose of this review is to describe shortly
the historical development of these methods as well as their
technical and methodological basics. To elucidate the large
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variety of possible applications, examples of SPECT and
PET procedures utilised in research as well as in clinical
practice are presented.
Historical development of SPECT and PET
The original suggestions towards SPECT and PET were al-
ready made in the early 1960s by Kuhl and Edwards [1] and
by Rankowitz and co-workers [2]. A successful introduction
of these approaches was, however, hindered by insufficient
reconstruction algorithms available at that time. Satisfying
algorithms became available with the invention and early
development of CT by Cormack [3] and Hounsfield [4].
The first commercial SPECT systems were developed in the
late 1970s, when conventional gamma cameras used for pla-
nar scintigraphy were put on a special stand allowing the
rotation of the gamma camera around a supine patient. Es-
pecially for cerebral applications, ring detector systems be-
came available. To improve the sensitivity of SPECT present
commercial systems use two, three or even four gamma
cameras. Besides the improved sensitivity the systems have
become more and more mechanically stable so that they are
utilised in clinical routine with measurement times down to
10 minutes.
Parallel to the development of SPECT, PET devices were
introduced – first mainly in research environments where
necessary cyclotrons for the production of the short-lived
positron emitters were often available. Most of those sys-
tems used ring or ring-like assemblies of sodium iodide
(NaI) detectors surrounding the patient. There has been
a steady improvement in PET systems with respect to sen-
sitivity and image resolution by using BGO crystals instead
of NaI crystals, by introducing block detector schemes and
3-dimensional acquisition techniques.
Physical and technical basics of SPECT and PET
The detector system
The primary element of each nuclear medicine detector sys-
tem is the scintillation detector. Fig. 1a shows such a detector
which consists of a scintillation crystal and a photomultiplier
at least. The scintillation crystal is sensitive to the energy
of γ -radiation that is emitted by radionuclides used in nu-
clear medicine, no matter whether they are single photon or
positron emitters. The γ -radiation excites the scintillator ma-
terial so that it emits light photons, a part of which hits the
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Fig. 1. A scintillation detector (left) consists of a scintillation crystal (a),
a photomultiplier (b), and a collimator (c) which restricts the direction
of the detected radiation. The gamma camera (right) consists of an ar-
ray of photomultipliers (b) mounted on a single NaI-scintillation crystal
(a) and a collimator (c). A network of resistors (d) is used to weight
the pulses of the different photomultipliers in order to localise (x) the
viewed radiation.
photocathode of the photomultiplier where they cause a pho-
toeffect producing electrons. These electrons are amplified
within the photomultiplier tube resulting in a voltage pulse
which is proportional to the number of light photons pro-
duced within the scintillation crystal and in this way propor-
tional to the energy of the incoming γ -radiation. Fig. 2 shows
the energy spectrum of the single photon emitter 99mTc. The
energy spectrum of this emitter with only one single γ -energy
consists of two parts. The photopeak has its maximum at the
γ -energy of the radionuclide. The Compton spectrum rep-
resents the energy distribution of those γ -photons that have
lost part of their energy by Compton scattering within the ob-
Fig. 2. Energy spectrum of the gamma emitter 99mTc consisting of pho-
topeak and Compton spectrum. The energy window of the gamma cam-
era with its lower energy level (LEL) and its upper energy level (UEL) is
centred at the maximum of the photopeak. There is an overlap between
the Compton distribution and the photopeak.
ject to be investigated or in the scintillation crystal. In order
to separate the true γ -radiation from that which has changed
its direction by Compton scattering, discrimination electron-
ics is used to distinguish between photopeak and Compton
distribution. The discriminator circuit defines a lower and
upper energy level so that the energy window within these
levels includes the photopeak. The measurement of the radi-
ation event by the scintillation detector must be completed
by the information about the direction of the radiation, if an
image of the activity distribution within the body is to be
constructed. In the case of single photon emitters this infor-
mation is obtained with the help of lead or tungsten colli-
mators which allow only that radiation to reach the detec-
tor which comes from a direction specified by the collimator
holes (Fig. 1). Data about uptake and outwash of activity into
and out of this organ, i.e. counts as a function of time, can
be obtained already with single scintillation detectors which
are positioned over an organ of interest. In order to get two-
dimensional image information an assembly of single scintil-
lation detectors has to be used such as is available in a gamma
camera (Fig. 1b). A gamma camera consists of one large NaI-
crystal on which an array of photomultipliers is mounted [5].
The light photons produced by a γ -ray within the NaI-crystal
are seen by several neighbouring photomultipliers. In order
to localise the entry of the γ -ray the signals produced by the
photomultipliers are weighted by an appropriate resistor net-
work. Furthermore, a collimator in front of the NaI-crystal
excludes nearly all radiation not coming from a direction per-
pendicular to the gamma camera surface. There are many
different kinds of collimators, e.g. to look in an oblique direc-
tion. They will, however, not be discussed here.
Whereas the existence of a mechanical collimator is
essential for measuring single photon emitters by planar
scintigraphy or SPECT, they are not necessary for PET
which utilises a so-called electronic collimation. Fig. 3
shows the physical basis of PET. Here, a positron is the
primary result of the radioactive decay. Depending on its
energy, which is specific for the individual radionuclide, it
travels a short distance between less than 1 mm and several
mm after which it is nearly at rest so that it is able to interact
with an electron of the surrounding material. As a result both
particles annihilate and produce a pair of photons which
are emitted in opposite directions and have an energy of
511 keV, each corresponding to the rest energy of one elec-
tron. In PET, scintillation detectors are mostly assembled as
a ring. If the two photons of a photon pair hit two detec-
tors of a ring within a very short time window (e.g. 12 ns)
it is assumed that these photons belong to the same annihila-
tion process (coincidence measurement, Fig. 3). Therefore,
the location of the radioactive atom is regarded to be on
the connecting line between the two detectors (= electronic
collimation). In this way information about the direction of
the γ -radiation is obtained without any mechanical colli-
mation. Until some years ago there was still a collimation
between neighbouring detector rings so that the γ -radiation
was guided within one plane, thus allowing for a two-
dimensional (2D) acquisition mode only. Modern PET to-
mographs offer a three-dimensional (3D) acquisition mode
for which detectors of neighbouring rings are also combined
by the coincidence electronics [6, 7]. Such 3D systems ex-
hibit a 3−5 fold increase of sensitivity over a 2D system.
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Fig. 3. Principle of coincidence measurement using a ring of scintil-
lation detectors with opposing detectors connected by a coincidence
electronics. The zoomed part scheme indicates the positron emission of
the radionuclide 18F and the emission of two photons of 511 keV after
the positron meets an electron.
Image reconstruction
Whereas planar imaging, such as conventional radiology or
planar scintigraphy, reduces the 3D distribution within the
body to projected 2D information, tomographic procedures
yield a fully 3D display. For this purpose projection data
must be acquired from many views around the body which
can be achieved by using a ring of detectors or by one or
more gamma cameras rotating around the patient [8]. The
basic relation which combines the projection data measured
outside the body and the activity concentration within the




A(x, y)dl(r, α) . (1)
This kind of equation was first presented by the German
mathematician Radon and is therefore called Radon trans-
form [9]. It relates the 2D activity distribution A(x, y) de-
scribed in cartisian coordinates and the line integrals P(r, α)
defined with polar coordinates. The line integral is the sum
of all photons measured by a detector looking at the body
with a specific angle α. The exact view of the detector is
defined by the polar coordinates r and α (see also Fig. 7).
Eq. (1) does not take into account the photons emitted by
the radioactivity, but absorbed and scattered within the body.
The amount of absorption and scattering is dependent on
the density and shape off the body tissue and on the phys-
ical characteristics of the radionuclide. There are consider-
able differences in handling these effects with SPECT and
PET. Provided these effects can be neglected or are satis-
factorily corrected the task to conclude from the recorded
projection data P(r, α) to the unknown activity concentra-
tion A(x, y), i.e. the solution of (1) with respect to A(x, y)
is identical for SPECT and PET. The mostly used recon-
struction method for obtaining A(x, y) is the filtered back-
projection [10]. According to the term backprojection the
data recorded from different views α are continuously pro-
jected back into the x, y plane. The superposition of all
backprojected data, however, yields only a blurred image of
the actual activity distribution. Therefore, this data must be
sharpened by using an appropriate filter, i.e. a ramp filter
which amplifies high rather than low frequency components
(Fig. 4). The resulting image represents the desired activity
concentration A(x, y). In many applications filtered back-
projection is the reconstruction method of choice, i.e. in
all studies where sufficient photons are recorded by the ra-
diation detectors and where the activity contrast between
nearby structures of interest is not high. If these two pre-
requisites are not fulfilled, streak artifacts become visible.
Such artifacts can be avoided with an alternative reconstruc-
tion method that calculates the activity image iteratively in
an algebraic way. This method can be derived from a sta-
tistical and a numerical point of view, the latter of which is
shortly described here. In this approach eq. (1) is rewritten
as a product of matrices
pn = zmnam . (2)
where pn is a matrix comprising all projection elements and
am represents the activity data at the image pixels m, i.e. the
unknown activity distribution. The members of the matrix
zmn describe in which way the coincidence events emitted
from image pixel m contribute to a single projection pn .
Commonly, this equation cannot be solved for the unknown
matrix am . Instead, it is solved in an iterative way; for in-










This equation represents the maximum likelihood (ML)
expectation-maximisation (EM) method for iterative recon-
struction [11]. The use of the iterative reconstruction is ad-
vised especially in the case of low counts and high contrast
images. An earlier disadvantage of this method was the very
long computation time – a problem which has been solved
by fast computers and the introduction of acceleration pa-
rameters [12] as well as the ordered subset method [13]. The
quantitative accuracy assured for the original ML-EM pro-
cedure may not be guaranteed for other solutions. Looking at
the literature many different suggestions for iterative recon-
Fig. 4. Principle of filtered backprojection. The different projection
data are backprojected into the imaging space and superimposed, re-
sulting in a blurred object from which the desired reconstructed object
is obtained after using ramp filtering.
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struction for both SPECT and PET applications have been
published in recent years [14].
As already explained above, the ramp (high pass) filter
is an integral part of the filtered backprojection and coun-
terbalances the low pass characteristics of the mere back-
projection. A severe disadvantage of high pass filtering is
the amplification of statistical noise present in the meas-
ured counts. Therefore, the ramp filter is limited to low
frequencies and/or multiplied with an appropriate window
function to weaken the high pass characteristics of the ramp
filter. Such window functions are the Hann, Shepp-Logan,
Hamming, Parzen, or the Butterworth window. Although
the reduction of the high frequency statistical noise is wel-
come, one has to consider that the image resolution becomes
worse compared to the use of the original ramp filter. The
decreased image resolution results in worse delineation of
small details and a reduction of the image maxima. The
decreased image resolution due to the use of a frequency-
limiting window has a similar consequence as the use of
a detector system with low intrinsic resolution. In both cases
the partial volume effect increases. This effect causes an un-
derestimation of the observed activity nearby low activities
and an overestimation nearby high activity concentrations
and is especially relevant for small structures. To reduce
such errors in combination with a satisfying suppression of
noise, the window functions and their upper frequency limit
have to be selected carefully.
Although iterative reconstruction does not involve a fil-
ter problem as just discussed, some other characteristics
must be taken into account. Generally, iterative reconstruc-
tion allows an image resolution near to the optimum scanner
resolution. In practice, however, the final image resolution
is dependent on the individual reconstruction algorithm and
on its specific implementation. Therefore, the resolution
performance of the individual program should be checked.
A general rule is that the resolution becomes better with the
number of iterations. Some iterative reconstruction proced-
ures such as the ML-EM method exhibit, however, high fre-
quency noise at many iterations, although the convergence
of the method is guaranteed. Furthermore, the increase of
noise is dependent on the specific program implementation.
To avoid such noise, modifications of the reconstruction al-
gorithms and/or a post processing filtering have been pro-
posed. In both cases the image resolution becomes worse so
that the partial volume effect is augmented and the quantita-
tive accuracy of PET may be reduced [15].
In order to reconstruct data acquired with 3D mode, appro-
priate algorithms of 3D-FBP have been developed [16, 17].
Although eq. (1) cannot exactly be solved for the case of 3D,
Fig. 5. Valid (t = true) and erroneous
radiation seen by a gamma camera
and/or a coincidence detector pair:
scattered radiation (s) and random
coincidences (r). A part of the radia-
tion is absorbed within the body (a).
The gamma camera accepts only
that information (t) which coincides
with the direction of the collimator
holes, whereas other photons are re-
jected (0).
several approaches for the 3D-FBP are successfully utilised
with commercial PET systems. In the meantime their quan-
titative accuracy has been proven to be satisfactory. Further-
more, it is possible to rebin the 3D data in 2D sinograms
so that they can be reconstructed as is known from the 2D
acquisition mode. In the case of single slice rebinning the
oblique projections are assembled into a 2D sinogram be-
longing to the plane in which they cross the central axis.
The method of multislice rebinning distributes the oblique
projections into the sinograms of those planes which are
crossed by the oblique projection [18]. The Fourier rebin-
ning method (FORE) applies a weighted distribution of the
2D sinograms so that the relationship between the direct
and the oblique plains are considered in a theoretically ex-
act way [19]. The 2D sinograms resulting from the different
rebinning methods can be reconstructed by the conventional
2D filter backprojection or by an iterative reconstruction
method.
Correction procedures
The information available in reconstructed SPECT or PET
images should be linear to the underlying activity, i.e.
a twofold activity concentration in a certain tissue must be
represented by a twofold pixel value in the reconstructed
image. On the other hand, the radiation emitted by the
activity is distorted in several ways before it reaches the
scintillation detectors and the acquisition electronics. On
their way through the body tissue the γ -rays may be scat-
tered and/or absorbed (Fig. 5). Furthermore, the dead time
of the detectors might lead to erroneous results. In PET ran-
dom coincidences have to be considered (Fig. 5b). In order
to guarantee the linearity of radiation measurement these
effects must be corrected [20].
Attenuation correction
As indicated by the following equations one of the major dif-
ferences between SPECT and PET concerns the correction
for those photons which have been absorbed within the body
(Fig. 5).
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Pcorr(r, α)= P(r, α)/AF =
∫
L(r,α)
A(x, y)dl(r, α) . (7)
The relationships of (5)–(7) are illustrated in Fig. 6. The
decisive advantage of PET is that the integral over the ac-
tivity distribution A(x, y) and the exponential expression
containing µ(x, y) are two factors of a product and can be
determined in two steps, one after the other. In order to cor-
rect the photon attenuation, the attenuation factor AF (6) is
usually determined by a transmission measurement of, for
example, 10 min mostly prior to the tracer injection. Be-
cause of this correction an equation (7) of the Radon form
(1) is obtained and can be solved as described above. The
attenuation correction is essential, if the PET measurement
is to be quantitative. If this correction is not done, e.g. to
shorten the acquisition time in whole-body studies, the PET
results can only be judged qualitatively. Furthermore, with-
out attenuation correction the reconstructed images show
severe distortions. Activity concentrations being the same
in the interior and at the border of the body, are imaged
totally differently with an overestimation of the activity at
the border. The PET image without attenuation correction
is not linear. A new approach which aims at a very short
transmission scan without loss of the signal to noise ratio is
the use of single photon emitters instead of positron emit-
ters for the transmission source. In this case more counts
can be measured in a much shorter time. If the transmis-
sion measurement is done with positron emitters only, one
photon is needed for the transmission information and the
other photon is just used to define the line of response (see
Fig. 6. In PET a transmission measurement yields attenuation factors to
correct for the absorption on the same lines along which the emission
scan records the coincidence events.
Fig. 6). If it is possible to define the line of response in
another way, e.g. by tracking the path of the transmission
source, positron emitters are no longer needed. Instead sin-
gle photon emitters with a similar photon energy, but a much
longer half-life can be utilised such as the single photon
emitter 137Cs with a photon energy of 662 keV [21, 22]. Due
to the higher photon energy, the measured attenuation data
differ from that valid for the 511 keV, although the trans-
mission image is practically identical. One way to correct
this difference is to adjust the measured attenuation fac-
tors to the photon energy of 511 keV. Another way is to
segment the reconstructed transmission image and to insert
the standard attenuation coefficients for the different tissues.
The last mentioned way results in noise-free attenuation fac-
tors AF. Using this approach the transmission time may be
decreased to only 10 minutes for five bed positions. Fur-
thermore, distortions between the different body parts are
avoided.
In contrast to PET, a transmission scan done in SPECT
does not directly enable an accurate attenuation correction,
because the integration path L ′(r, α) reaching from the point
of emission to the body surface remains unknown. There-
fore, the projection equation for SPECT (4) cannot be solved
analytically, e.g. by filtered backprojection. In some applica-
tions the attenuation term is just neglected assuming µ= 0,
i.e. the attenuation coefficient of air. In spite of this simpli-
fication SPECT without attenuation correction proved to be
very useful in many clinical applications, especially heart
studies (see below). Looking at the brain or abdomen it may
be justified to assume a constant µ, namely that of water
with a value of 0.154 cm−1. To allow a pre-reconstruction
attenuation correction the projection data are acquired com-
pletely around the patient, then opposite views are geometri-
cally averaged (Fig. 7). Because of this combination and by
assuming a constant µ for the tomographic section to be re-
constructed the following factor AF for the co-called first
order attenuation correction can be derived [23]:
AF = (1− exp(−µl)) /µl , (8)
Fig. 7. Principle of measuring opposite projections to enable a first
order attenuation correction of SPECT data.
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so that the projection equation for this approach reads:
Pcorr(r, α)= Pgeo(r, α)/AF =
∫
L(r,α)
A(x, y)dl(r, α) . (9)
Here similar to PET, the filtered backprojection sums pro-
jections just over one half-circle. Based on this approach
a second order attenuation correction for SPECT data has
been developed, introducing one or more (iterative) post-
processing steps to increase the accuracy of the correc-
tion [24].
Scatter correction
As shown in Fig. 5 a photon may change its direction within
the body because of Compton scatter. Such photons cause
a low-frequency background and decrease the image con-
trast. The primary means to eliminate them is energy dis-
crimination. The Compton scatter results in a loss of energy
so that these photons contribute to the Compton distribu-
tion shown in Fig. 2. The electronic energy discrimination
defines an energy window around the photopeak where the
lower threshold is to separate between scattered and non-
scattered photons. As indicated in Fig. 2. there is always
a small overlap. On the other hand the lower energy thresh-
old must be set not too high in order not to lose too much un-
changed photons – and sensitivity. The width of the energy
window expressed as percentage of the mean photopeak en-
ergy is dependent on the light output of the scintillation crys-
tal material. In this respect, NaI, which is used for SPECT,
is more favourable than BGO. In spite of its wider energy
window BGO is found in most PET-scanners, because its
density is more adequate for the 511 keV energy of the PET
photons than that of NaI.
Since it is not possible to exclude all scattered photons
by energy discrimination additional procedures for correc-
tion have to be implemented. A lot of different methods have
been suggested. The simplest procedure is to modify the
first order attenuation correction by using a µ of 0.12 cm−1
instead of 0.154 cm−1. By weakening the attenuation correc-
tion the scatter correction is included in some way. A major
approach is the dual-energy window technique. Here data
are recorded in the photopeak window as well as in a win-
dow covering the Compton distribution. It is assumed that
the scattered photons PCompton measured within the Compton
window and within the photopeak have a fixed ratio k so that
a correction can be done according
Pcorr = Ppp − k · PCompton , (10)
where Ppp are all – nonscattered and scattered – events
registered within the photo-peak [25]. A basic problem
is that k is very object-dependent. In addition to this
simple method more sophisticated correction methods
have been developed [26–28] so that the quantitative ac-
curacy of SPECT has improved considerably for many
applications.
Although being basically the same the scatter problem
in PET differs in some aspects from that found in SPECT.
Due to the higher photon energy the amount of scattered
photons is less. On the other hand modern PET scanners
offer the 3D-acquisition mode, where septa that prevent
scatter are retracted so that 50% of the measured coinci-
dences may be scattered. One correction method utilises the
Klein-Nishina model of scatter and requires the additional
transmission measurement to get knowledge about the scat-
ter material [29]. An easier procedure has been suggested by
Stearns [30]. For the 2D-measurement mode a point- source
is measured in air and in water, so that a scatter function can
be modelled and a convolution-subtraction-based correction
model is applied [31]. In spite of the corrections there may
be a residual scatter fraction of 5 to 10%. A specific problem
for 3D-PET is scattered radiation coming from outside the
field of view. Here the ideal method would be the dual en-
ergy approach applied to each detector element which needs,
however, a considerable increase in cost for electronics.
Dead time correction
All scintillation detectors exhibit a dead time effect if the
measured count rate is high. The dead time is dependent
on all (non-scattered and scattered) photons seen by the de-
tectors. To correct the dead time a calibration measurement
is performed which relates the counts originating from an
activity source with the photons actually measured by the in-
dividual detector modules. In regard to PET the dead time
is not just dependent on the rate of coincidences, but on all
photons, which also include photons originating from activ-
ity outside the field of view.
Correction for random coincidences
This type of correction is specific for PET. A random coin-
cidence occurs if two single photons belonging to two dif-
ferent positron emissions are registered by two opposing de-
tectors within the coincidence time window and are falsely
regarded as a coincidence event (Fig. 5b). The random co-
incidences cause a low frequent background. There are two
procedures to correct the random coincidences. A hardware
based method uses a delayed coincidence time window hav-
ing the same length as the original coincidence window. All
coincidences counted in the second interval are regarded as
being random and directly subtracted from the measured
(prompt) coincidences. The second method performs a cal-
culated correction [32]. In this case the single count rates Si
of the individual detectors are measured as well. Knowing
these count rates and the duration τ of the coincidence time
window the random coincidences R are
R = 2τSi Sj , (11)
which are subtracted from the measured coincidences as
a prereconstruction step.
SPECT applications
Relevant clinical applications of SPECT imaging can be
found for practically all organs of the body from brain over
lung, heart, liver down to the legs. Looking at the literature
most publications refer to cardiological and neurological
questions. A specific characteristic of SPECT is that the ac-
quisition time of SPECT with its detectors slowly rotating
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around the patient is longer than that of the PET ring de-
tector systems. An essential prerequisite of SPECT is that
the distribution of the radiopharmaceutical injected into the
patient remains practically stationary during the detector ro-
tation around the patient. Therefore, SPECT radiopharma-
ceuticals must be tailored so that after their uptake into an
organ they show a slow outwash. Furthermore, the half-life
of the radionuclide must be sufficiently long. For dynamic
acquisitions a rotation time of 2 min may be appropriate to
record a single time frame with a triple-head SPECT sys-
tem, which yields high quality static image in 15 min, for
example.
The success of nuclear medicine in general, but also
of SPECT is strongly coupled to an artificial radionuclide,
namely 99mTc. It emits a monoenergetic single photon radi-
ation of 140 keV (see Fig. 2). Furthermore 99mTc has a con-
venient half-life of about 6 hours (not too short for purpose
of storage and imaging and not too long for purpose of
dosimetry), and is available with a generator system deliv-
ered weekly to the customer [33]. Therefore in contrast to
PET, SPECT does not depend on a nearby cyclotron. Over
the years the radiopharmaceutical industry has developed
many kits which contain dry precursor compounds to be
labelled with 99mTc. In addition, there are other photon emit-
ters used, such as 123I or 201Tl with a half-life of 13.2 h and
3 d, respectively.
A specific advantage of SPECT is the possibility of mul-
titracer studies where different radiopharmaceuticals, each
with another radionuclide (and a separate γ -energy), are in-
jected at the same time or in combination. Practically all
gamma-cameras allow multiple window studies with differ-
ent energy windows so that a separation of the radionuclides
is possible.
Neurological SPECT
The majority of SPECT imaging of the brain uses 99mTc la-
belled HMPAO [34] or ECD [35] (sometimes still
123I-IMP [36] – especially in Japan) to trace the regional
cerebral blood flow (rCBF). Mostly, decreases of rCBF are
looked for, as they occur in a variety of brain disorders.
Fig. 8 shows a typical example related to the diagnosis of
Morbus Alzheimer. In Alzheimer’s dementia a typical pat-
tern of low perfusion in the region of the occipito-parietal
cortex is found and can help in the differential diagnosis
among other kinds of dementia. Also, in epilepsy, rCBF-
SPECT has shown its value [37]. If the rCBF-SPECT is
done between epileptic seizures (inter-ictal), a localised de-
crease of tracer uptake is regarded as being concordant with
the epileptic focus. If, however, the study is done during or
immediately after an epileptic seizure (ictal and peri-ictal,
respectively), the epileptic focus is delineated by increased
blood flow. It has been shown that the subtraction of inter-
ictal images from ictal images yields an even better diag-
nostic sensitivity [38]. Immediately after brain infarction,
rCBF-SPECT is able to show perfusion changes, in spite of
a still normal CT. At a later stage areas, which show a de-
creased rCBF, indicate functional deficits caused by lacking
input (afferences) from the infarcted region.
Although originally a domain of PET, more and more
neurotransmitter studies are found in the SPECT literature.
Fig. 8. In comparison to a normal subject there is less radioactivity in
the occipito-parietal cortex of a patient with Alzheimer’s disease (ar-
rows). This finding can be visualised by SPECT using 99mTc-HMPAO
(indicating decrease of blood flow) as well as 18F-FDG-PET (indicat-
ing a corresponding decrease of glucose metabolism).
Most of these compounds are labelled with 123I. The size
of this atom is appropriate to substitute a methyl group
during the radiochemical labelling. In contrast to PET,
where a labelling with 11C does not change the biochem-
ical behaviour of a pharmaceutical, an altered behaviour
must be taken into account when using 123I. The long half-
life of 123I may be an advantage over PET because the
SPECT scan can be done many hours after the injection
which might be favourable for some applications. A re-
cent example is 123I-β-CIT, which is a tracer of the cerebral
dopamine transport. It shows an optimum image quality one
day after injection. 123I-β-CIT yields similar results as the
PET tracer 18F-L-Dopa by showing a decreased uptake in
the striatum of patients with Morbus Parkinson [39]. Other
123I-labelled tracers are the dopamine2 receptors ligands
123I-IBZM [40] or 123I-IBF [41] and the central benzodi-
azepine receptor ligand 123I-iomazenil [42]. These tracers
have been tested in various neurological and psychiatric
disorders [43]. Many other 123I-labelled neurotransmitter
tracers have been suggested during the last years, which
cannot be detailed here.
123IMT, a radiolabelled amino acid, has proved to be very
useful in the delineation of brain tumours [44] giving similar
results as the PET tracer 11C-methionine (Fig. 9) [45]. Com-
pared to FDG (see below) complementary information about
the tumour extension may be obtained.
Cardiological SPECT
In daily clinical routine most SPECT studies deal with
the heart. Here, radiotracers such as 99mTc-MIBI [46],
99mTc-tetrofosmin [47], or still 201Tl [48] are used to study
myocardial perfusion, especially if there are signs of coro-
nary artery disease, such as angina pectoris. The common
protocol is to combine a rest study with a stress study so
that badly perfused areas are delineated by decreased tracer
uptake during the stress study with its increased energy de-
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Fig. 9. Increased uptake of a radiolabelled amino acid in an astrocy-
toma grad II shown by SPECT using 123I-α-methyl-tyrosine as well
as by PET using the natural amino acid methionine which remains
biochemically unchanged by the labelling with 11C.
mand. The stress is induced by exercising or dobutamine
injection. Myocardial perfusion tracers may also be used to
follow up the results after bypass surgery or percutaneous
transluminal coronary angioplasty (PTCA). The advantages
of 99mTc-labelled perfusion tracers compared to the former
standard imaging agent 201Tl are the better imaging quality
and the availability of the generator product 99mTc.
123I-labelled fatty acids have been designed to exam-
ine myocardial energy metabolism which is based on the
oxidation of fatty acids by about 60%. 123I-HDA [49],
123I-BMIPP [50] and 123I-pPPA [51] and have been applied
as a tool to investigate patients with cardiomyopathy [52].
Disorders of the autonomous myocardial innervation
which are found, e.g., with dilative cardiomyopathy, heart
transplantation, and diabetes have been examined with
123I-MIGB [53] (Fig. 10).
Oncological SPECT
Although the diagnosis and the follow up of malignant tu-
mours is primarily the task of planar radiology, CT, MRT,
or ultrasound, nuclear medicine can help in the case of un-
Fig. 10. Decreased uptake of 123I-MIBG in the posterior myocardium
indicating a disorder of the autonomous cardiac innervation in a di-
abetic patient. The perfusion marker 99mTc-MIBI displays a normal
perfusion.
clear findings and in specifying the tumour type by utilising
its specific ability of metabolic, receptor, and antigen imag-
ing. Examples are iodine storing metastases of a thyroid
malignancy and phosphate-sensitive bone metastases caused
by many carcinoma. In many cases planar imaging is suf-
ficient, whereas SPECT may be necessary to improve the
spatial delineation. Unlike PET, which offers 18F-FDG to
visualise a lot of different tumour types, SPECT must se-
lect that tracer which is appropriate for the tumour type
to be investigated as indicated by the following examples.
111In-octreotide is appropriate for the visualisation of so-
matostatin receptor expressing tumours [54]. 123I-MIBG is
also used for the diagnosis of pheochromocytoma and neu-
roblastoma [55]. 67Ga has been applied in the follow-up
of lymphoma treatment [56] and lung cancer [57]. Further-
more, the immunoscintigraphy of tumours is based on many
different monoclonal antibodies labelled with 99mTc, 123I, or
111In [58].
Other SPECT applications
SPECT has also been used to study liver diseases using
99mTc-sulphur-colloids [59] and 99mTc-GSA [60]. Cavernous
hemangioma in the liver and other vascular abnormalities
in the abdomen have been visualised with 99mTc-labelled
blood cells [61, 62]. SPECT studies of the kidneys have been
performed with 99mTc-DSMA as an indicator of the tubu-
lar renal function [63]. 67Ga has been applied in different
questions, e.g. in lung cancer [57], in lymphoma after treat-
ment [56], and in different infections [64]. SPECT has pro-
vided important diagnostic and prognostic information for
orthopaedic problems related to the lower extremities [65].
PET applications
Often PET is regarded just as a research tool which is too
expensive to become of general importance for clinical rou-
tine. The change of this situation becomes obvious by the
rapid world-wide increase of PET scanners from several
dozens in 1990 to more than 300 in 2000. The short half-
life of the mostly used positron emitters ranging from 2 min
for 15O, 10 min for 13N, 20 min for 11C to 109 min for 18F
and the necessity of a nearby cyclotron to produce these
radionuclides is one of the reasons for the relatively slow
expansion of PET. On the other hand 18F-labelled deoxyglu-
cose (FDG) has proved to be very valuable for many clinical
applications and can be shipped from a cyclotron to PET
sites within a radius of several hundred kilometres. Since
1979 FDG, which originated from Sokoloff’s work with
14C-labelled deoxyglucose [66] for the study of cerebral glu-
cose metabolism, has been successfully used in neurology,
cardiology, and more recently especially in oncology.
Oncological PET
In many different tumours FDG-PET is able to visualise
recurrent malignant tumours, their metastases and in some
cases unknown primary tumours better than other imaging
modalities such as CT or MRT [67]. Furthermore, FDG-
PET is useful in the follow-up of radio- or chemotherapy
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Fig. 11. The whole-body PET examination after the injection of FDG
delineates three metastases (arrows) from prostate cancer not revealed
by other imaging procedures.
when blood tumour markers indicate the existence of a re-
current or of metastases which cannot be delineated by CT
or MRT. These advantages are the main reason for the re-
cent world-wide increase of PET. Fig. 11 shows an example
of the delineation of metastases not being seen by other
methods.
Neurological PET
The primary use of FDG was in research and clinical stud-
ies of the brain [68, 69]. Since the brain receives 90% of
its energy by the oxidation of glucose, the glucose ana-
logue FDG is able to indicate hypo- or hyperfunctions.
Diminished uptake of FDG indicating cerebral hypofunc-
tion is found in epilepsy (Fig. 12), infarction, or demen-
tia [70]. Because of the close coupling of cerebral blood flow
and cerebral glucose consumption in normal tissue [71],
but also in many diseases, the aim of FDG-PET is simi-
lar to that of perfusion studies with SPECT. Although many
of these studies are done with SPECT nowadays, there is
still a demand for PET if the specific question requires the
still superior image resolution of PET. This may be the
case when looking for a small epileptic hypometabolic fo-
cus [37].
If parts of the brain become very active compared to
others because of an external or mental stimulation, these
areas of hyperfunction can be delineated by increased up-
Fig. 12. Decrease of FDG in the area of the right temporal lobe de-
lineating the suspected epileptic focus of a patient suffering from
seizures. The image of magneto-resonance tomography (MCI) shows
no disorder.
take of FDG. In the last years, such investigations have
utilised 15O-water or 15O-butanol so that a sequence of
different stimulations can be measured due to the rapid
decay of the short-lived radionuclide 15O (e.g. 1. rest,
2. slow thumb movements, 3. faster thumb movements,
4. very fast thumb movements). After intravenous injec-
tion these tracers are distributed within the brain in cor-
relation to rCBF. Hundreds of such studies have been
performed by neuroscientists so that many details of the
motor and sensory systems as well as of higher cogni-
tive processes could be delineated. An example of such
a study which involves learning and memory [72] is given
in Fig. 13. In addition to many questions related to basic
research, neuroactivation studies can be advantageous for
the single patient. For example, it is possible to delineate
important language or motor control areas in the vicin-
ity of a malignant brain tumour before it is removed by
surgery.
There are hundreds of other positron-emitting radio-
pharmaceuticals, especially neurotransmitter ligands and
amino acids which have been suggested for studies of
the brain. Amino acids such as 11C-methionine (Fig. 9)
are especially appropriate to help in the differential di-
agnosis of malignant brain tumours and in follow up
studies [73]. Radiopharmaceuticals with an affinity to the
neurotransmitter system have been applied in neurologi-
cal and psychiatric research, e.g. in Parkinson’s disease
Fig. 13. During the learning (a) of uncorrelated word pairs (e.g. house-
river, piano-street) there is a maximum of increased blood flow in the
left frontal cortex (arrow). During the retrieval (b) of one part of the
word pairs there is an additional activation in the right frontal cor-
tex (arrows). Only maxima of increased blood flow are displayed on
a surface view of a standard MRI-image.
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and other motor disorders, in depression and schizophre-
nia [74–77]. Whereas first knowledge about the neuro-
transmitter system is usually acquired by animal research
or post-mortem studies, PET can verify these findings in
the human being in vivo. The radioactive labelling is of-
ten done with the positron emitter 11C (half-life = 20 min)
so that the biochemical characteristics of the labelled trans-
mitter molecules are unchanged [78]. The tracer kinetic
analysis of the PET data leads to the determination of the
binding potential, the density of neuroreceptors, and the
binding affinity between receptor and drugs. Only few neu-
rotransmitter ligands have reached clinical relevance such
as 18F-L-Dopa which is of help in the differential diag-
nosis of Parkinson’s disease and in the follow up of the
treatment [79]. A very interesting research area with pos-
sible implications to clinical routine is the study of the
interaction between psychopharmaceuticals and specific
PET compounds such as the dopamine receptor ligand
11C-raclopride [80] or the serotonergic receptor ligand 18F-
altanserin [81].
Cardiological PET
A third clinical field where PET has been successful is car-
diology. Using blood flow indicators such as 13NH3 [82],
15O-water [83], or 82Rb [84] cardiac flow studies have
been performed analogously to those done with SPECT
(Fig. 14) [85]. Although PET yields a better resolution
and is very favourable to combine a rest and an exercise
study by using short-lived isotopes, just these isotopes have
hindered the wide-spread use of this method due to the ne-
cessity of a nearby cyclotron or an expensive generator (for
82Rb). An even more important indication of cardiac PET
is to define viable tissue in the neighbourhood of an infarc-
tion [86]. Since badly perfused myocardial tissue near to
an infarction shows a relatively high uptake of FDG, this
finding can be used to decide whether this tissue is still
viable so that it will profit from a therapeutical interven-
tion such as bypass surgery or PTCA. If the myocardial
tissue is not viable, such an intervention is not necessary.
As already seen in SPECT, fatty acids are used to study the
myocardial energy metabolism. Here the natural amino acid
palmitate is labelled with 11C to study cardiomyopathy, for
instance [87].
Fig. 14. PET images of myocardial uptake of the heart blood flow
tracer 13N-ammonia in a normal volunteer at rest (a) and during in-
jection of dipyridamole (b) which increases blood flow similar to
exercising. The increased blood flow is especially visualised by the
lower background.
SPECT vs. PET
Although specific characteristics of SPECT and PET have
already been compared above, some of the most import-
ant relationships and differences between these two tomo-
graphic modalities of nuclear medicine are to be summarised
here. Because of the electronic collimation PET offers a bet-
ter sensitivity with a factor up to 100 over SPECT. The pos-
sibility to do an accurate transmission measurement and an
exact attenuation correction is the main reason for PET to be
quantitative. In contrast SPECT is regarded as more qualita-
tive yielding count rates rather than being calibrated with the
physical entity of activity per volume. Nevertheless, there
has been a considerable progress in the last years in improv-
ing the quantitative capabilities of SPECT. Because of the
better sensitivity PET is able to record shorter time frames
in dynamic studies. The radiolabelling of metabolically ac-
tive molecules by the positron emitters 11C, 13N, or 15O does
not change the biochemical behaviour of the radiolabelled
molecule so that the development of new radiopharmaceu-
ticals can be based on prior biomedical knowledge. SPECT
radiopharmaceuticals are considered being “unnatural” so
that their introduction often needs more time, involving ba-
sic investigations and sometimes many vain trials. In spite of
its quantitative and radiochemical advantages the availabil-
ity of PET has remained rather limited due to the higher cost
of the scanners and for the cyclotron and radiochemistry. As
mentioned above, the progression of SPECT radiochemistry
in the last years gave the possibility to transfer original ex-
perience made by PET research to the cheaper, more widely
available and routinely used clinical tool SPECT. The only
PET radiopharmaceutical for which SPECT does not of-
fer an analogue is FDG, the working horse of PET. Here
a bridge between PET and SPECT has been constructed by
the introduction of dual-head coincidence gamma cameras.
In addition to the normal SPECT mode, these double-headed
SPECT systems offer the retraction of the mechanical col-
limators together with the combination of the electronics of
the two gamma camera detectors by coincidence circuitry.
In this way the SPECT instrument can also be used for PET
imaging. Although the overall performance of such systems
is inferior to dedicated PET systems they allow the use of
FDG which has become especially important in oncology
applications if the more cost-intensive PET instruments are
not available.
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